Moderna reported positive Phase 3 data for its seasonal influenza vaccine mRNA-1010, demonstrating a 26.6% relative efficacy over a standard-dose comparator in adults 50 years and older across multiple influenza strains. The vaccine showed a consistent safety profile with mostly mild adverse effects and may pave the way for a combined COVID-19 and influenza shot. The data bolster Moderna's plans for regulatory submissions, aiming for possible launch in the 2026-2027 flu season.